SVA
Sinovac Biotech Ltd
6.50$
+0.0%
vs. previous close
Closing price · As of: Sep 12, 2026
Statements
Cash Flow
Sinovac Biotech Ltd (SVA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -510 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.3 | -0.5 | -0.5 | -0.1 | -1.7 | -1.5 | -1.1 | -1.6 | 4.3 | 11 | 48 | -14 | 14 | -16 | 5.6 | -10 | 4.2 | -15 | 60 | 7.9 | 39 | 479 | 15,353 | -771 | 106 | -57 | -510 | |
| 0.0 | 0.0 | 0.0 | 0.1 | 0.7 | 0.9 | 0.9 | 1.3 | 1.4 | 1.8 | 2.2 | 4.2 | 4.8 | 4.5 | 6.4 | 8.1 | 6.5 | 5.3 | 4.9 | 5.1 | 4.8 | 4.0 | 87 | 157 | 145 | 114 | 104 | |
| – | – | – | – | – | 0.4 | – | -0.1 | 2.7 | 0.1 | 0.4 | 0.5 | 0.2 | 0.3 | 0.3 | 0.3 | 1.0 | 2.4 | 1.0 | 4.3 | 3.0 | 10 | 7.7 | 149 | 0.0 | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | 1.3 | – | 0.0 | 0.9 | 1.0 | 0.1 | 9.0 | 25 | 18 | 82 | – | – | – | – | – | |
| 0.0 | 0.0 | 0.0 | 0.0 | -1.3 | -1.6 | -1.6 | -4.6 | -8.2 | -3.8 | 15 | -14 | 2.9 | -6.9 | -10 | -19 | -2.3 | -20 | 20 | -44 | -28 | 283 | 461 | -1,081 | 278 | -123 | -377 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 1.7 | 1.7 | 1.1 | 2.5 | 4.0 | 4.3 | 25 | 15 | 16 | 5.1 | 11 | 5.3 | 13 | 12 | 5.6 | 11 | 128 | 720 | 403 | 146 | 98 | 49 | |
| – | – | 0.0 | 0.0 | -0.7 | -3.0 | – | -0.6 | -2.4 | -4.0 | -12 | -19 | -14 | -16 | -5.2 | -11 | -4.5 | -12 | -12 | -25 | -42 | -205 | -3,024 | -5,760 | -2,926 | – | 4,386 | |
| – | – | – | 1.0 | – | – | 0.4 | 0.4 | – | 2.9 | 3.8 | 3.3 | – | – | 0.6 | 0.6 | 0.0 | 0.0 | 0.0 | 0.0 | – | 0.0 | 1,876 | 263 | 328 | 947 | 3,513 | |
| – | 0.0 | 0.0 | 1.0 | 1.0 | 5.5 | 7.0 | 0.9 | 0.2 | -0.4 | -0.3 | 20 | 0.8 | 0.5 | 0.8 | 0.6 | 0.8 | 0.3 | 1.7 | 85 | – | – | 21 | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | 13 | 1.2 | -25 | 21 | -5.6 | -25 | -1.2 | 574 | -26 | -4.3 | 239 | 123 | 100 | |
| 0.5 | 0.4 | 0.4 | 0.1 | 3.6 | 5.8 | 6.5 | 4.0 | 5.6 | 8.3 | 5.3 | 58 | 0.6 | 17 | 14 | 5.3 | -24 | 28 | -1.3 | 64 | 1.7 | 593 | -1,897 | -241 | -76 | -824 | -3,435 | |
| 0.1 | -0.1 | -0.1 | 0.0 | 1.1 | 1.2 | 1.2 | 1.9 | 7.8 | 16 | 42 | 27 | 2.7 | -13 | 15 | -17 | -26 | -1.4 | 51 | 42 | -2.3 | 894 | 10,570 | -7,333 | -3,011 | -527 | 554 | |
| -0.4 | -0.5 | -0.5 | -0.1 | -2.5 | -3.2 | -2.8 | -2.8 | 1.8 | 6.5 | 44 | -40 | -1.5 | -32 | 0.4 | -21 | -1.1 | -28 | 48 | 2.3 | 28 | 352 | 14,633 | -1,174 | -42 | -154 | -559 |
Data as of: September 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.